Business
PureTech's Vor Raises $110M Series B Financing
PureTech's Vor Raises $110M Series B Financing.
About this update from Puretech Health Plc
[{"type":"text","content":"\n \n \n RNS Number : 1863S\n PureTech Health PLC\n 06 July 2020\n \n \n \n \n 7 July 2020\n \n \n PureTech Health plc\n \n \n \n \n \n PureTech Founded Entity Vor Biopharma Raises $110 Million in Series B Financing\n \n \n \n \n \n Proceeds will advance the company's lead programme into clinical trials and expand the portfolio\n \n \n \n \n \n Financing led by RA Capital Management, with Participation from Fidelity Management & Research Company, LLC, Pagliuca Family Office, Alexandria Venture Investments, 5AM Ventures, Johnson & Johnson Innovation - JJDC, Inc. (JJDC) and Osage University Partners\n \n \n \n \n \n \n \n PureTech Health plc\n \n \n (LSE: PRTC) (\"PureTech\"\n \n or the \"Company\"), a clinical-stage biotherapeutics company dedicated to discovering, developing and commercialising highly differentiated medicines for devastating diseases, is pleased\n \n \n to note that its Founded Entity, Vor Biopharma, has raised $110 million in a Series B financing. \n \n Proceeds will advance the company's lead candidate VOR33 into clinical trials, deepen its portfolio and accelerate the validation of additional targets for its scientific platform, which is designed to remove redundant proteins so that transplanted stem cells become invisible to targeted therapies while leaving diseased cells vulnerable. Vor's treatment strategy has the potential to bring a revolutionary treatment paradigm for patients with acute myeloid leukaemia and other haematologic malignancies. \n \n \n \n \n \n Founded by PureTech and Siddhartha Mukherjee, MD, DPhil, Vor is developing engineered haematopoietic stem cell (eHSC) therapies for the treatment of cancer.\n \n \n \n \n \n Bharatt Chowrira, JD, PhD, PureTech's president and chief of business and strategy, said: \"Vor is breaking new ground with its eHSCs therapies for treating cancer, which are designed to hide healthy cells from targeted therapies while leaving diseased cancer cells vulnerable to attack. This financing with top tier investors is a strong testament to the strength of this scientific platform and its potential to make a difference for cancer patients.\" \n \n \n \n \n \n The full text of the announcement from Vor is as follows:\n \n \n \n \n \n \n \n Vor Biopharma Closes $110 Million Series B Financing\n \n ...